Related Experiment Video
Updated: Jan 14, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Carfilzomib resistance in multiple myeloma: A comparative metabolomic analysis
Krzysztof Żyłka1,2, Magdalena Łuczak3, Magdalena Kostrzewska-Poczekaj4,5
1Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Ul. Szamarzewskiego 84, 60-569, Poznan, Poland.
Abstract:
Proteasome inhibitors are currently at the forefront of multiple myeloma (MM) treatment. Drug resistance in MM challenges treatment, causing relapses and making the disease incurable. Urgent strategies are needed to combat resistance and understand its mechanisms. Targeting the metabolism of MM is a promising approach, as metabolic changes are associated with the disease and its adaptation to therapy. Metabolomics, the study of small molecule metabolites, is a powerful tool for identifying and analyzing a cell's metabolic phenotype. In this study, we aimed to investigate alterations in the metabolome of carfilzomib-resistant MM cells. We conducted global metabolomic comparative analyses of two carfilzomib-sensitive MM lines with their carfilzomib-resistant progenies. Additionally, we performed bioinformatic analysis to determine the top canonical pathways, biological functions, and upstream regulators linked to the differences in metabolomic profiles. Differential metabolite analysis showed increased amino acid and decreased fatty acid concentrations in carfilzomib-resistant cells. Functional analysis revealed increased glucose-6-phosphate oxidation and inhibited lipid accumulation in resistant lines. The bioinformatic analysis predicted PML, ARNT D-glucose, and UPC1 as upstream regulators of observed changes in carfilzomib-resistant cells. This study presents one of the first metabolomic profiles of two carfilzomib-resistant MM lines and the metabolome changes that may contribute to carfilzomib resistance.
Insights
Drug resistance in multiple myeloma (MM) is a major challenge. This study reveals key metabolic shifts, including altered amino acid and fatty acid levels, in carfilzomib-resistant MM cells, offering new therapeutic targets.
Area of Science:
- Oncology
- Metabolomics
- Biochemistry
Background:
- Proteasome inhibitors like carfilzomib are crucial for multiple myeloma (MM) treatment.
- Drug resistance in MM leads to treatment failure and disease relapse.
- Understanding resistance mechanisms, particularly metabolic adaptations, is vital for developing new therapies.
Purpose of the Study:
- To investigate metabolic alterations in carfilzomib-resistant MM cells using metabolomics.
- To identify key metabolic pathways and regulators involved in carfilzomib resistance.
- To provide a metabolomic profile of resistant MM cells for future therapeutic strategies.
Main Methods:
- Comparative global metabolomic analysis of carfilzomib-sensitive and resistant MM cell lines.
- Bioinformatic analysis to identify canonical pathways, biological functions, and upstream regulators.
- Differential metabolite analysis to quantify changes in small molecule concentrations.
Main Results:
- Carfilzomib-resistant MM cells exhibited increased amino acid and decreased fatty acid concentrations.
- Functional analysis indicated enhanced glucose-6-phosphate oxidation and suppressed lipid accumulation in resistant cells.
- Bioinformatic analysis identified PML, ARNT D-glucose, and UPC1 as potential upstream regulators.
Conclusions:
- Metabolic reprogramming, including changes in amino acid and lipid metabolism, is associated with carfilzomib resistance in MM.
- This study provides novel metabolomic insights into carfilzomib resistance mechanisms.
- Targeting identified metabolic pathways and regulators may offer strategies to overcome drug resistance in MM.
